09926 AKESO
- 49.000
- +0.200+0.41%
AKESO News
Kangfang Biology (9926.HK) company follow-up review: Cardonelli's gastric cancer data is impressive, and the whole population benefits significantly
Kangfang Biology (9926.HK): Cardonelli's gastric cancer data is impressive, and the whole population benefits significantly
Kang Fang Biology (09926.HK): AK104 rapid release, AK112, Pan-catalysis
Kangfang Biotech (09926.HK) Review Report: The performance is in line with expectations, and the domestic listing of Evosi is imminent
Kangfang Biology (09926.HK): Cardonelli's sales growth is strong, and development of various products is progressing rapidly
Bank Rating | Citibank: Raising Kangfang Biotech's Target Price to HK$64 to Maintain “Buy” Rating
Bank Rating | CMB International: Raised Kangfang Biotech's target price to HK$59.61, I believe this year will be another “good harvest year”
Kang Fang Biotech (9926.HK): The pipeline matrix is rich, and multiple products will be approved, and revenue is expected to continue to increase.
Kangfang Biology (9926.HK): Commercialization has entered an accelerated period, multiple data disclosures and product launch catalysts are worth looking forward to
Macquarie: The target price for Kangfang Biotech (09926)'s “Outperform the Market” rating was raised to HK$56
Kangfang Biotech (9926.HK): Performance is in line with expectations, Iwasi is about to enter the harvest period
Kangfang Biology (9926.HK) 2023 Annual Report Review: Strong innovative research and development capabilities, commercialization of various products can be expected in the future
Citibank: Maintaining Kangfang Biotech's (09926) “Buy” rating and raising the target price to HK$64
Kangfang Biotech (9926.HK): The results of the mid-term analysis of the first phase three trial between Ivorsi and K Pharmacol are expected to be announced at the end of the second quarter
Kangfang Biology (09926.HK): Cardonil increased by 149%, Ivoracil and others are expected to be approved
AKESO BIOTECH(09926.HK):CONTINUOUS SALES RAMP UP WITH R&D ACHIEVEMENTS
Kangfang Biotech (9926.HK): Performance is in line with expectations, and evosimab is expected to be launched
Kangfang Biotech (9926.HK): Strong performance in 2023, and the target price will increase in a year that will soon enter the catalyst to blossom more
Bank Rating | Lyon: Raising BeiGene's Target Price to HK$138.5, Reiterating the “Buy” Rating
Nomura Adjusts Akeso's Price Target to HK$52.80 From HK$48.84, Keeps at Buy
Analysis
Price Target
No Data
